Acumen Pharmaceuticals (ABOS) Competitors

Acumen Pharmaceuticals logo
$0.20 -0.03 (-14.82%)
As of 03:34 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ABOS vs. KALA, ATRA, CRDF, PMVP, and KVAC

Should you buy Acumen Pharmaceuticals stock or one of its competitors? Acumen Pharmaceuticals's main competitors and comparable companies include KALA BIO (KALA), Atara Biotherapeutics (ATRA), Cardiff Oncology (CRDF), PMV Pharmaceuticals (PMVP), and Keen Vision Acquisition (KVAC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Acumen Pharmaceuticals compare to KALA BIO?

Acumen Pharmaceuticals (NASDAQ:ABOS) and KALA BIO (NASDAQ:KALA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Comparatively, 2.2% of KALA BIO shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Acumen Pharmaceuticals currently has a consensus price target of $1.00, indicating a potential upside of 334.59%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Acumen Pharmaceuticals is more favorable than KALA BIO.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acumen Pharmaceuticals
3 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.71
KALA BIO
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Acumen Pharmaceuticals' return on equity of -166.49% beat KALA BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
Acumen PharmaceuticalsN/A -166.49% -90.79%
KALA BIO N/A -222.35%-70.23%

In the previous week, KALA BIO had 4 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 4 mentions for KALA BIO and 0 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 0.41 beat KALA BIO's score of -0.28 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Acumen Pharmaceuticals Neutral
KALA BIO Neutral

Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acumen PharmaceuticalsN/AN/A-$121.33M-$1.54N/A
KALA BION/AN/A-$26.98M-$31.96N/A

Acumen Pharmaceuticals has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, KALA BIO has a beta of -2.19, meaning that its share price is 319% less volatile than the broader market.

Summary

Acumen Pharmaceuticals beats KALA BIO on 9 of the 13 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Atara Biotherapeutics?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Acumen Pharmaceuticals currently has a consensus price target of $1.00, indicating a potential upside of 334.59%. Atara Biotherapeutics has a consensus price target of $9.50, indicating a potential upside of 46.15%. Given Acumen Pharmaceuticals' higher possible upside, equities analysts plainly believe Acumen Pharmaceuticals is more favorable than Atara Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acumen Pharmaceuticals
3 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.71
Atara Biotherapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

Acumen Pharmaceuticals has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -368.58%. Atara Biotherapeutics' return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Acumen PharmaceuticalsN/A -166.49% -90.79%
Atara Biotherapeutics -368.58%N/A -73.19%

In the previous week, Atara Biotherapeutics had 4 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 4 mentions for Atara Biotherapeutics and 0 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 0.41 beat Atara Biotherapeutics' score of 0.06 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Acumen Pharmaceuticals Neutral
Atara Biotherapeutics Neutral

Atara Biotherapeutics has higher revenue and earnings than Acumen Pharmaceuticals. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acumen PharmaceuticalsN/AN/A-$121.33M-$1.54N/A
Atara Biotherapeutics$120.77M0.55$32.69M-$1.01N/A

Acumen Pharmaceuticals has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market.

Summary

Atara Biotherapeutics beats Acumen Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Cardiff Oncology?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

In the previous week, Cardiff Oncology had 14 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 14 mentions for Cardiff Oncology and 0 mentions for Acumen Pharmaceuticals. Cardiff Oncology's average media sentiment score of 0.71 beat Acumen Pharmaceuticals' score of 0.41 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company Overall Sentiment
Acumen Pharmaceuticals Neutral
Cardiff Oncology Positive

Acumen Pharmaceuticals has a net margin of 0.00% compared to Cardiff Oncology's net margin of -6,736.49%. Cardiff Oncology's return on equity of -111.80% beat Acumen Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Acumen PharmaceuticalsN/A -166.49% -90.79%
Cardiff Oncology -6,736.49%-111.80%-81.51%

Acumen Pharmaceuticals currently has a consensus price target of $1.00, indicating a potential upside of 334.59%. Cardiff Oncology has a consensus price target of $7.50, indicating a potential upside of 786.11%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Cardiff Oncology is more favorable than Acumen Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acumen Pharmaceuticals
3 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.71
Cardiff Oncology
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 10.2% of Acumen Pharmaceuticals shares are owned by company insiders. Comparatively, 8.8% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cardiff Oncology has higher revenue and earnings than Acumen Pharmaceuticals. Cardiff Oncology is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acumen PharmaceuticalsN/AN/A-$121.33M-$1.54N/A
Cardiff Oncology$590K111.60-$45.85M-$0.55N/A

Acumen Pharmaceuticals has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

Summary

Cardiff Oncology beats Acumen Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to PMV Pharmaceuticals?

Acumen Pharmaceuticals (NASDAQ:ABOS) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acumen PharmaceuticalsN/AN/A-$121.33M-$1.54N/A
PMV PharmaceuticalsN/AN/A-$77.74M-$1.54N/A

Acumen Pharmaceuticals has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

Acumen Pharmaceuticals presently has a consensus target price of $1.00, indicating a potential upside of 334.59%. PMV Pharmaceuticals has a consensus target price of $4.33, indicating a potential upside of 255.19%. Given Acumen Pharmaceuticals' higher possible upside, equities research analysts plainly believe Acumen Pharmaceuticals is more favorable than PMV Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acumen Pharmaceuticals
3 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.71
PMV Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Comparatively, 10.2% of PMV Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, PMV Pharmaceuticals had 10 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 10 mentions for PMV Pharmaceuticals and 0 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 0.41 beat PMV Pharmaceuticals' score of -0.59 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Acumen Pharmaceuticals Neutral
PMV Pharmaceuticals Negative

PMV Pharmaceuticals' return on equity of -91.39% beat Acumen Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Acumen PharmaceuticalsN/A -166.49% -90.79%
PMV Pharmaceuticals N/A -91.39%-72.22%

Summary

PMV Pharmaceuticals beats Acumen Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Keen Vision Acquisition?

Keen Vision Acquisition (NASDAQ:KVAC) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Keen Vision Acquisition has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

51.7% of Keen Vision Acquisition shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 80.2% of Keen Vision Acquisition shares are held by company insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Acumen Pharmaceuticals' average media sentiment score of 0.41 beat Keen Vision Acquisition's score of 0.00 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Keen Vision Acquisition Neutral
Acumen Pharmaceuticals Neutral

Keen Vision Acquisition's return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Keen Vision AcquisitionN/A N/A N/A
Acumen Pharmaceuticals N/A -166.49%-90.79%

Acumen Pharmaceuticals has a consensus price target of $1.00, suggesting a potential upside of 334.59%. Given Acumen Pharmaceuticals' higher possible upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Keen Vision Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Keen Vision Acquisition
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Acumen Pharmaceuticals
3 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.71

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Keen Vision AcquisitionN/AN/AN/AN/AN/A
Acumen PharmaceuticalsN/AN/A-$121.33M-$1.54N/A

Summary

Acumen Pharmaceuticals beats Keen Vision Acquisition on 5 of the 9 factors compared between the two stocks.

Get Acumen Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABOS vs. The Competition

MetricAcumen PharmaceuticalsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$14.18M$3.97B$7.59B$11.71B
Dividend YieldN/A3.63%2.47%4.46%
P/E Ratio-0.1324.5933.6329.90
Price / SalesN/A15.678.455.70
Price / CashN/A22.9521.0121.90
Price / Book0.414.174.463.73
Net Income-$121.33M-$24.10M$3.51B$393.84M
7 Day Performance-14.78%-8.21%-6.33%-5.93%
1 Month Performance-88.40%-6.32%-4.73%-7.24%
1 Year Performance-88.19%-6.58%-1.55%-7.43%

Acumen Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABOS
Acumen Pharmaceuticals
3.1086 of 5 stars
$0.20
-14.8%
$1.00
+410.2%
-85.4%$14.18MN/AN/A61
KALA
KALA BIO
0.7759 of 5 stars
$3.43
-10.4%
N/A-99.7%$66.34MN/AN/A6
ATRA
Atara Biotherapeutics
3.0453 of 5 stars
$6.50
+1.6%
$9.50
+46.2%
-50.4%$66.24M$120.77MN/A10
CRDF
Cardiff Oncology
1.9684 of 5 stars
$0.85
-0.2%
$7.50
+786.1%
-58.9%$65.84M$590KN/A31
PMVP
PMV Pharmaceuticals
2.6849 of 5 stars
$1.22
+2.5%
$4.33
+255.2%
-14.1%$65.22MN/AN/A54

Related Companies and Tools


This page (NASDAQ:ABOS) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners